S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Shocking Transcript: Financial Chaos Now Brace yourself for what's coming next (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
NASDAQ:PSTX

Poseida Therapeutics - PSTX Stock Forecast, Price & News

$4.40
+0.29 (+7.06%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.91
$4.55
50-Day Range
$2.00
$4.51
52-Week Range
$1.82
$11.10
Volume
1.07 million shs
Average Volume
673,060 shs
Market Capitalization
$276.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.33

Poseida Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
316.7% Upside
$18.33 Price Target
Short Interest
Bearish
5.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.63mentions of Poseida Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Acquiring Shares
$8.03 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.43) to ($3.23) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.57 out of 5 stars

Medical Sector

128th out of 1,117 stocks

Biological Products, Except Diagnostic Industry

21st out of 175 stocks

PSTX stock logo

About Poseida Therapeutics (NASDAQ:PSTX) Stock

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Poseida Therapeutics Trading Up 6.3 %

Shares of Poseida Therapeutics stock traded up $0.26 during trading hours on Friday, reaching $4.37. 13,530 shares of the company's stock were exchanged, compared to its average volume of 3,732,693. Poseida Therapeutics has a 52-week low of $1.82 and a 52-week high of $11.10. The firm has a market capitalization of $361.53 million, a price-to-earnings ratio of -1.76 and a beta of 0.52. The company has a fifty day moving average of $2.69 and a 200-day moving average of $3.28. The company has a current ratio of 4.34, a quick ratio of 4.34 and a debt-to-equity ratio of 0.56.

Poseida Therapeutics (NASDAQ:PSTX - Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.93) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.35). The company had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.50 million. Sell-side analysts forecast that Poseida Therapeutics will post -3.43 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on PSTX. Piper Sandler upped their target price on Poseida Therapeutics from $9.00 to $11.00 and gave the company an "overweight" rating in a research note on Tuesday. Cantor Fitzgerald began coverage on Poseida Therapeutics in a research note on Friday, May 13th. They issued a "buy" rating and a $24.00 target price on the stock. Finally, BTIG Research reduced their target price on Poseida Therapeutics from $40.00 to $20.00 and set a "buy" rating on the stock in a research note on Friday, May 13th.

Insider Buying and Selling

In other news, Chairman Eric Ostertag bought 142,857 shares of the business's stock in a transaction that occurred on Monday, August 8th. The shares were acquired at an average cost of $3.50 per share, with a total value of $499,999.50. Following the transaction, the chairman now owns 838,824 shares of the company's stock, valued at approximately $2,935,884. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, major shareholder Life Sciences Holdings L. Malin purchased 2,150,000 shares of the stock in a transaction that occurred on Monday, August 8th. The stock was purchased at an average cost of $3.50 per share, for a total transaction of $7,525,000.00. Following the acquisition, the insider now owns 11,835,673 shares in the company, valued at $41,424,855.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Eric Ostertag purchased 142,857 shares of the stock in a transaction that occurred on Monday, August 8th. The stock was bought at an average price of $3.50 per share, with a total value of $499,999.50. Following the completion of the acquisition, the chairman now owns 838,824 shares in the company, valued at approximately $2,935,884. The disclosure for this purchase can be found here. Corporate insiders own 29.20% of the company's stock.

Receive PSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PSTX Stock News Headlines

See More Headlines
Receive PSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PSTX Company Calendar

Last Earnings
11/09/2021
Today
8/12/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PSTX
Fax
N/A
Employees
263
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.33
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+316.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-124,970,000.00
Pretax Margin
-442.92%

Debt

Sales & Book Value

Annual Sales
$31.24 million
Book Value
$2.50 per share

Miscellaneous

Free Float
44,412,000
Market Cap
$276.01 million
Optionable
Not Optionable
Beta
0.52

Key Executives

  • Dr. Eric M. Ostertag M.D. (Age 49)
    Ph.D., Exec. Chairman
    Comp: $667.42k
  • Mr. Mark J. Gergen J.D. (Age 59)
    CEO & Director
    Comp: $659.53k
  • Ms. Johanna M. Mylet CPA (Age 35)
    Chief Financial Officer
  • Ms. Kristin Martin
    Chief People & Admin. Officer
  • Sarah Thailing
    Sr. Director of Corp. Communications & IR
  • Mr. Harry J. Leonhardt Esq. (Age 65)
    J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Dr. Devon J. Shedlock Ph.D.
    Chief Scientific Officer of Cell Therapies
  • Ms. Lisa Portale
    Sr. VP of Regulatory Affairs
  • Mr. Brent Warner (Age 38)
    Pres of Gene Therapy













PSTX Stock - Frequently Asked Questions

Should I buy or sell Poseida Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Poseida Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PSTX shares.
View PSTX analyst ratings
or view top-rated stocks.

What is Poseida Therapeutics' stock price forecast for 2022?

4 equities research analysts have issued 1-year price targets for Poseida Therapeutics' shares. Their PSTX share price forecasts range from $11.00 to $24.00. On average, they predict the company's share price to reach $18.33 in the next year. This suggests a possible upside of 316.7% from the stock's current price.
View analysts price targets for PSTX
or view top-rated stocks among Wall Street analysts.

How have PSTX shares performed in 2022?

Poseida Therapeutics' stock was trading at $6.81 on January 1st, 2022. Since then, PSTX shares have decreased by 35.4% and is now trading at $4.40.
View the best growth stocks for 2022 here
.

When is Poseida Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our PSTX earnings forecast
.

How were Poseida Therapeutics' earnings last quarter?

Poseida Therapeutics, Inc. (NASDAQ:PSTX) released its earnings results on Tuesday, November, 9th. The company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.06.

What other stocks do shareholders of Poseida Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Poseida Therapeutics investors own include Moderna (MRNA), Advanced Micro Devices (AMD), AngloGold Ashanti (AU), Micron Technology (MU), Eaton (ETN), Corning (GLW), OPKO Health (OPK), Overstock.com (OSTK), Sorrento Therapeutics (SRNE) and SSR Mining (SSRM).

When did Poseida Therapeutics IPO?

(PSTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair served as the underwriters for the IPO.

What is Poseida Therapeutics' stock symbol?

Poseida Therapeutics trades on the NASDAQ under the ticker symbol "PSTX."

Who are Poseida Therapeutics' major shareholders?

Poseida Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (11.37%), Silverarc Capital Management LLC (0.61%), JPMorgan Chase & Co. (0.37%) and Forefront Analytics LLC (0.04%). Insiders that own company stock include Eric Ostertag, Kerry D Ingalls, Life Sciences Holdings L Malin, Matthew A Spear and Sean Murphy.
View institutional ownership trends
.

How do I buy shares of Poseida Therapeutics?

Shares of PSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Poseida Therapeutics' stock price today?

One share of PSTX stock can currently be purchased for approximately $4.40.

How much money does Poseida Therapeutics make?

Poseida Therapeutics (NASDAQ:PSTX) has a market capitalization of $276.01 million and generates $31.24 million in revenue each year. The company earns $-124,970,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis.

How many employees does Poseida Therapeutics have?

The company employs 263 workers across the globe.

How can I contact Poseida Therapeutics?

Poseida Therapeutics' mailing address is 9390 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.poseida.com. The company can be reached via phone at 858-779-3100.

This page (NASDAQ:PSTX) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.